Switch theme
Sign up to access all valuation multiples
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
1999
16
LTM Revenue $63.3M
LTM EBITDA $32.9M
$220M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clinuvel Pharma has a last 12-month revenue (LTM) of $63.3M and a last 12-month EBITDA of $32.9M.
In the most recent fiscal year, Clinuvel Pharma achieved revenue of $56.6M and an EBITDA of $36.2M.
Clinuvel Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clinuvel Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $63.3M | XXX | $56.6M | XXX | XXX | XXX |
| Gross Profit | $58.1M | XXX | $50.2M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $32.9M | XXX | $36.2M | XXX | XXX | XXX |
| EBITDA Margin | 52% | XXX | 64% | XXX | XXX | XXX |
| EBIT | $32.2M | XXX | $30.8M | XXX | XXX | XXX |
| EBIT Margin | 51% | XXX | 54% | XXX | XXX | XXX |
| Net Profit | $25.0M | XXX | $22.9M | XXX | XXX | XXX |
| Net Margin | 39% | XXX | 40% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Clinuvel Pharma's stock price is AUD 11 (or $7).
Clinuvel Pharma has current market cap of AUD 540M (or $347M), and EV of AUD 343M (or $220M).
See Clinuvel Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $220M | $347M | XXX | XXX | XXX | XXX | $0.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Clinuvel Pharma has market cap of $347M and EV of $220M.
Clinuvel Pharma's trades at 3.7x EV/Revenue multiple, and 6.4x EV/EBITDA.
Equity research analysts estimate Clinuvel Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Clinuvel Pharma has a P/E ratio of 13.9x.
See valuation multiples for Clinuvel Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $347M | XXX | $347M | XXX | XXX | XXX |
| EV (current) | $220M | XXX | $220M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.9x | XXX | 14.4x | XXX | XXX | XXX |
| EV/FCF | 10.2x | XXX | 10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialClinuvel Pharma's last 12 month revenue growth is 8%
Clinuvel Pharma's revenue per employee in the last FY averaged $3.5M, while opex per employee averaged $1.2M for the same period.
Clinuvel Pharma's rule of 40 is 72% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Clinuvel Pharma's rule of X is 72% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Clinuvel Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 52% | XXX | 58% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 72% | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clinuvel Pharma acquired XXX companies to date.
Last acquisition by Clinuvel Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Clinuvel Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Clinuvel Pharma founded? | Clinuvel Pharma was founded in 1999. |
| Where is Clinuvel Pharma headquartered? | Clinuvel Pharma is headquartered in Australia. |
| How many employees does Clinuvel Pharma have? | As of today, Clinuvel Pharma has 16 employees. |
| Who is the CEO of Clinuvel Pharma? | Clinuvel Pharma's CEO is Dr. Philippe J. Wolgen, M.B.A.,M.D.. |
| Is Clinuvel Pharma publicy listed? | Yes, Clinuvel Pharma is a public company listed on ASX. |
| What is the stock symbol of Clinuvel Pharma? | Clinuvel Pharma trades under CUV ticker. |
| When did Clinuvel Pharma go public? | Clinuvel Pharma went public in 2001. |
| Who are competitors of Clinuvel Pharma? | Similar companies to Clinuvel Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Clinuvel Pharma? | Clinuvel Pharma's current market cap is $347M |
| What is the current revenue of Clinuvel Pharma? | Clinuvel Pharma's last 12 months revenue is $63.3M. |
| What is the current revenue growth of Clinuvel Pharma? | Clinuvel Pharma revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Clinuvel Pharma? | Current revenue multiple of Clinuvel Pharma is 3.5x. |
| Is Clinuvel Pharma profitable? | Yes, Clinuvel Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Clinuvel Pharma? | Clinuvel Pharma's last 12 months EBITDA is $32.9M. |
| What is Clinuvel Pharma's EBITDA margin? | Clinuvel Pharma's last 12 months EBITDA margin is 52%. |
| What is the current EV/EBITDA multiple of Clinuvel Pharma? | Current EBITDA multiple of Clinuvel Pharma is 6.7x. |
| What is the current FCF of Clinuvel Pharma? | Clinuvel Pharma's last 12 months FCF is $21.5M. |
| What is Clinuvel Pharma's FCF margin? | Clinuvel Pharma's last 12 months FCF margin is 34%. |
| What is the current EV/FCF multiple of Clinuvel Pharma? | Current FCF multiple of Clinuvel Pharma is 10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
